Myriad Genetics (NASDAQ:MYGN) Upgraded to Buy at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of Myriad Genetics (NASDAQ:MYGN – Get Rating) from a sell rating to a buy rating in a research report sent to investors on Tuesday, The Fly reports. They currently have $25.00 target price on the stock, up from their prior target price of $18.00. MYGN has been the subject […]